

How to find, filter, and format Evidence-based Information on the Benefits and on the Risks of Medicines



Prof. Dr. R. Vander Stichele

Heymans Institute of Pharmacology

University of Ghent, Belgium

Brussels, UCL , December 16, 2013

Disclosure

I am a general practitioner and a clinical pharmacologist,
with many interests,
but no conflicts of interests,

Board member / co-founder of :

- CEBAM : Belgian Centre for Evidence-Based Medicine
- CDLH : Cebam Digital Library of Health
- EBMPpracticeNET : Belgian Platform for Guidelines

Senior advisor of :

- Belgian Centre of Pharmaco-therapeutic Information

A discrepancy in pharmaceutical information

Evidence-based information on efficacy

Based on Randomized Controlled Trials

Synthesis extremely well developed since 1990


Evidence-based information on patient Safety


Based on anecdotal pharmacovigilance and
observational pharmaco-epidemiology


Still in its infancy


Evidence on efficacy of medication


Timeline EBM : international (1992 – now)











An example of aggregation of high level evidence on efficacy in guidelines on behavioral problems in dementia



Contents lists available at [ScienceDirect](#)

Ageing Research Reviews

journal homepage: www.elsevier.com/locate/arr



Review

Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms

Majda Azermai^{a,*}, Mirko Petrovic^{a,b}, Monique M. Elseviers^{a,c}, Jolyce Bourgeois^a,
Luc M. Van Bortel^a, Robert H. Vander Stichele^a

^a Ghent University, Heymans Institute of Pharmacology, Ghent, Belgium

^b Ghent University Hospital, Service of Geriatrics, Ghent, Belgium

^c University of Antwerp, Nursing Science, Antwerp, Belgium

ARTICLE INFO

Article history:

Received 1 July 2011

Accepted 8 July 2011

Available online xxx

ABSTRACT

Background: Within the treatment of dementia, management of behavioural and psychological symptoms (BPSD) is a complex component.

Purpose: We wanted to offer a pragmatic synthesis of existing specific practice recommendations for managing BPSD, based on agreement among systematically appraised dementia guidelines.

And for evidence on patient safety ?

Find evidence :

For each the relevant topics, what are the relevant sources of information ?

- SPC
- National drug Information Centre
- Handbooks
- Bibliographic indexes
- Trustworthy sites
- Exhaustive electronic resources,
to be integrated in EHR systems

Filter evidence :

- Which information items will be integrated
 - in electronic decision support systems ?
(Senator, Prima)
 - in audit of pharmaceutical quality ?
(Beers, ACOVE, Phebe, Bednurse, Stopp-Start)
- Only those that are clinically and epidemiologically relevant ?
 - To be determined by which method and which cut-off ?

Format evidence :

- How will we integrate the selected information items (clinically and epidemiologically relevant) into structured knowledge bases ?
- How good will the rule-based studies work in the environment of the EHR ?
- How will we present alerts and remarks to the clinicians ?

An example

**Identification of medications
with a clinically important
anticholinergic profile**

Eur J Clin Pharmacol
DOI 10.1007/s00228-013-1499-3

PHARMACOEPIDEMIOLOGY AND PRESCRIPTION

Systematic review of anticholinergic risk scales in older adults

**Carlos E. Durán • Majda Azerman •
Robert H. Vander Stichele**

Background

- Anticholinergic (muscarin) side effects :
 - peripheral adverse effects (dry mouth, dry eyes, constipation, blurred vision and increased heart rate)
 - central adverse effects (Dizziness, sedation, confusion, delirium and even cognitive impairment)
- Medications with anticholinergic side-effects in many therapeutic areas
- Related with serious negative outcomes on the older adults
- Several attempts were made to produce reliable lists of anticholinergic drugs, with a gradation of potency.
- Considerable variation exists in the methodology of anticholinergic risk scale development.

Objective

- To systematically review existing anticholinergic risk scales and
- to develop a uniform list of anticholinergic drugs with differentiation in anticholinergic potency.

Method

- We searched the literature for anticholinergic scales, expressing the potency of selected medications
- Only scales based on a validation study were included
 - (relation with (clinical) outcome)
- Congruence between the potency estimation of the selected scales was examined.
- For drugs with a concordant potency estimation, the result was accepted and reduced to a potency estimation varying from 0 to 2 (no, low and high potency)
- When the estimation of anticholinergic potency was discordant, a handbook (Martindale) was used as gold standard.

Results

- 454 articles screened, 62 studies selected,
- 7 risk scales included

47 high potency anticholinergic drugs

53 low potency anticholinergic drugs

All classified in the Anatomical Chemical Therapeutic Classification

80 drugs mentioned in at least one scale,
but no consensus and no confirmation in Martindale

Further work

Link potency to dosage

Mimimal effective dosis

Normal dose

Dose adapted for the elderly

Maximum dose

Build an analytic algorithm to assess medication lists

Validate in a clinical study

General Conclusion

The methodology to filter and format
clinically and epidemiologically relevant
evidence-based information
on safety of medication
is its infancy.

Progress might come rapidly.